Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 1
2007 1
2008 1
2009 2
2010 1
2012 1
2013 1
2014 2
2016 3
2017 1
2018 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Pancreatic cancer: Update on immunotherapies and algenpantucel-L.
McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. McCormick KA, et al. Among authors: vahanian nn. Hum Vaccin Immunother. 2016 Mar 3;12(3):563-75. doi: 10.1080/21645515.2015.1093264. Hum Vaccin Immunother. 2016. PMID: 26619245 Free PMC article. Review.
Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Coveler AL, et al. Among authors: vahanian nn. Immunotherapy. 2016 Feb;8(2):117-25. doi: 10.2217/imt.15.113. Epub 2016 Jan 20. Immunotherapy. 2016. PMID: 26787078 Review.
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Zakharia Y, McWilliams RR, Rixe O, Drabick J, Shaheen MF, Grossmann KF, Kolhe R, Pacholczyk R, Sadek R, Tennant LL, Smith CM, Kennedy EP, Link CJ Jr, Vahanian NN, Yu J, Shen SS, Brincks EL, Rossi GR, Munn D, Milhem M. Zakharia Y, et al. Among authors: vahanian nn. J Immunother Cancer. 2021 Jun;9(6):e002057. doi: 10.1136/jitc-2020-002057. J Immunother Cancer. 2021. PMID: 34117113 Free PMC article. Clinical Trial.
A phase I study of indoximod in patients with advanced malignancies.
Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. Soliman HH, et al. Among authors: vahanian nn. Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216. Oncotarget. 2016. PMID: 27008709 Free PMC article. Clinical Trial.
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, Janik JE, Khleif SN. Nayak-Kapoor A, et al. Among authors: vahanian nn. J Immunother Cancer. 2018 Jun 20;6(1):61. doi: 10.1186/s40425-018-0351-9. J Immunother Cancer. 2018. PMID: 29921320 Free PMC article. Clinical Trial.
15 results